Cargando…

Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

Detalles Bibliográficos
Autores principales:	Qiao, Tianyun, Zhao, Jinbo, Xin, Xiangbing, Xiong, Yanlu, Guo, Wenwen, Meng, Fancheng, Li, Hui, Feng, Yangbo, Xu, Hui, Shi, Changhong, Han, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110673/ https://www.ncbi.nlm.nih.gov/pubmed/36571598 http://dx.doi.org/10.1007/s00262-022-03342-x

Ejemplares similares

Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model
por: Qiao, Tianyun, et al.
Publicado: (2022)

Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model
por: Qiao, Tianyun, et al.
Publicado: (2021)

TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway
por: Xiong, Yanlu, et al.
Publicado: (2021)

Gene expression-based clinical predictions in lung adenocarcinoma
por: Xiong, Yanlu, et al.
Publicado: (2020)

A gene-based survival score for lung adenocarcinoma by multiple transcriptional datasets analysis
por: Xiong, Yanlu, et al.
Publicado: (2020)

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
por: Feng, Yangbo, et al.
Publicado: (2018)

Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy
por: Guo, Wenwen, et al.
Publicado: (2021)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Correction to: Spleen metastasis of recurrent malignant thymoma
Publicado: (2023)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Correction: Phase 2 study of pembrolizumab in patients with advanced rare cancers
Publicado: (2020)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report
por: Liu, Mei, et al.
Publicado: (2022)

Bevacizumab in recurrent glioblastoma
por: Martinez, Nina L., et al.
Publicado: (2019)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
por: Xiong, Fan, et al.
Publicado: (2020)

Correction: Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells
por: Heo, Jang Won, et al.
Publicado: (2012)

Correction to: MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2022)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Correction: Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed
por: Zhang, Nasha, et al.
Publicado: (2017)

Correction to: Cerebral nocardiosis in a patient treated with pembrolizumab: a first case report
por: Petitgas, Paul, et al.
Publicado: (2022)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab
por: Hatayama, Tomoya, et al.
Publicado: (2020)

Evaluation of Serum Fructosamine as Diagnostic Marker of Postoperative Recurrence in the Patients with Breast Cancer
por: Zhao, Yuanqing, et al.
Publicado: (2023)

Correction to: Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy
por: Jiang, Wei, et al.
Publicado: (2022)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Chamberlain, Marc C.
Publicado: (2011)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
por: Liu, Yanxin, et al.
Publicado: (2023)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Case report: Postoperative abdominal recurrence of pulmonary pleomorphic carcinoma showed a dramatic response to S-1 after pembrolizumab
por: Kojima, Yuichi, et al.
Publicado: (2021)

Choroidal metastasis: Radiation and bevacizumab at presentation
por: Maheshwari, Abhilasha, et al.
Publicado: (2023)

Effects of Anesthesia on Postoperative Recurrence and Metastasis of Malignant Tumors
por: Fan, Xiaoqing, et al.
Publicado: (2020)

Pattern of disease and response to pembrolizumab in recurrent cervical cancer
por: Miller, Kathryn M., et al.
Publicado: (2021)

Recurrent Erythema Multiforme Induced by the Combination of Pembrolizumab and Radiation
por: Ambur, Austin B, et al.
Publicado: (2021)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
por: Lee, Yong Jae, et al.
Publicado: (2021)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report
por: Sato, Shoki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_357smknfnf1fcdofb86hcpt2i9